M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
PCI Biotech reports second dose group completed in phase I/II Amphinex trial
Norwegian biopharmaceutical company PCI Biotech (Oslo:PCIB) declared on Tuesday the completion of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex used in combination with the cytotoxic agent bleomycin in cancer patients.
The company stated that seven...
If you want to view the full text of this story, you must first purchase archive retrieval credits.